Clinical Trials


AT-014 Osteosarcoma Vaccine

Aratana Logo.JPG

Reprinted from American Veterinarian Article - January 5th, 2018

"Osteosarcoma is the most common primary bone tumor in dogs, but a new vaccine is striving to change that narrative. Aratana Therapeutics, a company focused on innovative therapeutics for dogs and cats, announced that their Canine Osteosarcoma Vaccine, Live Listeria Vector (AT-014), has been granted a conditional license by the United States Department of Agriculture (USDA) Center for Veterinary Biologics.

The vaccine uses a listeria-based antigen delivery system that activates cytotoxic T-cells. This directs the T-cells to fight off cancer cells—capitalizing on the dog’s immune system and its ability to attack bacterial infections.

"We know that most of these dogs relapse with metastatic disease, so clearly cancer is left after chemotherapy," said Nicola J. Mason, BVetMed, PhD, assistant professor of medicine and pathobiology at the University of Pennsylvania School of Veterinary Medicine and principal investigator of clinical trials investigating the new vaccine. "And we were asking the question: Could this vaccine induce an immune response which would eliminate those remaining cancer cells?”

During a clinical trial, researchers evaluated 18 dogs with primary tumor removal and gave them 4 doses of carboplatin chemotherapy followed by the new canine osteosarcoma vaccine every 3 weeks for 3 doses. The median survival rate was 956 days with the vaccine, compared with 423 days in a historical control group."



We’re conducting a clinical study for dogs with osteosarcoma who have undergone amputation and chemotherapy. There are eligibility requirements for your dog to participate in the study for the conditionally licensed Canine Osteosarcoma Vaccine, Live Listeria Vector and your veterinarian will review your dog’s medical history, perform a physical exam, take thoracic radiographs, and submit routine blood and urine tests.

If you would like to learn more, please contact us at  425-697-2272 for more information.

Gold Nanoparticles

Nanoparticles treatment.jpg

We are conducting a trial for dogs with small mast cell tumors (<1.25cm) and oral squamous cell carcinoma in cats. This new clinical trial utilizes gold nanoparticles in a gross disease setting.

Gold Nanoparticles are inert and are given IV to the patient and after a period of time the patient comes back to have the tumor heated with a laser. As the tumor vasculature is heated through the external near infrared spectrum of light, the gold nanoparticles are excited, the laser energy is converted to heat and the tumor vasculature is disrupted killing the tumor from the inside out.


1. Small mast cell tumors of <1.25cm size in all dimensions - reduced cost of trial to client.


2. Oral squamous cell carcinoma in cats - FUNDED by Companion Animal Health, Inc up to to $1400.

- Oral squamous cell carcinoma cases must be accessible with the laser probe and so tonsillar and under the tongue are not candidates.


If you have a potential case to discuss or have a patient with a small mast cell tumor in a bad location for surgery or if you would like to learn more,
please contact us at 425-697-2272 for more information.